Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 15/20 | 0.66 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8246690 | 0.95 | AURKA (0.70) | AURKAAURKBUSP30CHEK1GPR119 | |
| SCHEMBL12404510 | 0.90 | AURKA (0.67) | AURKAAURKBCHEK1LCKKDR | |
| SCHEMBL14538650 | 0.89 | AURKA (0.72) | AURKAAURKBCHEK1LCKKDR | |
| SCHEMBL12404508 | 0.89 | AURKA (0.71) | AURKAAURKBCHEK1LCKKDR | |
| SCHEMBL12404515 | 0.87 | AURKA (0.64) | AURKAAURKBCHEK1LCKKDR | |
| SCHEMBL12404514 | 0.86 | AURKB (0.71) | AURKAAURKBCHEK1LCKKDR | |
| SCHEMBL12404517 | 0.85 | AURKA (0.68) | AURKAAURKBCHEK1LCKKDR | |
| SCHEMBL14538376 | 0.83 | AURKB (0.74) | AURKAAURKBCHEK1LCKKDR | |
| SCHEMBL8247165 | 0.83 | AURKA (0.74) | AURKAAURKBCHEK1LCKKDR | |
| SCHEMBL8240362 | 0.82 | AURKB (0.88) | AURKAAURKBCHEK1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| WO-2007056468-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | AURKA 41/4885AURKB 138/4885USP30 1066/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | AURKA 5/4885AURKB 24/4885USP30 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.